Treatment Options for Multicentric Castleman's Disease
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
Siltuximab is now approved for multicentric Castleman’s disease > >
Clinical Pearls
Frits van Rhee, MD, PhD, MRCP, professor of medicine, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, discusses treatment options for multicentric Castleman's disease.
- Multicentric Castleman's disease is a benign lymph node disorder in which patients get sick and notice lumps and bumps.
- There is currently no standard of care for this group of patients who are not infected with HIV.
- Being a rare disease, there have been no large studies conducted in this space.
- Steroids and rituximab are commonly used to treat this disease.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
